Leland Gershell

Stock Analyst at Oppenheimer

(0.67)
# 2358
Out of 5,344 analysts
151
Total ratings
33.91%
Success rate
-8.63%
Average return
46 Stocks
Name Action PT Current % Upside Ratings Updated
XERS Xeris Biopharma Hold...
Maintains: Outperform
6 7
4.84 44.63% 2 May 9, 2025
ARGX argenx
Maintains: Outperform
704 708
588.14 20.38% 7 May 9, 2025
QNCX Quince Therapeutics
Initiates Coverage On: Outperform
10
1.1 809.09% 1 Mar 24, 2025
TRVI Trevi Therapeutics
Maintains: Outperform
12 20
6.29 217.97% 3 Mar 11, 2025
BMRN Biomarin Pharmaceuti...
Upgrades: Outperform
98
57.53 70.35% 3 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
76
62.36 21.87% 1 Dec 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
190 180
161.93 11.16% 10 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
48 52
18.44 182% 2 Nov 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
135 147
101.77 44.44% 2 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
5 5
0.5 900% 8 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 2 Nov 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 73
76.88 -5.05% 8 Oct 28, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
40 40
4.17 859.23% 9 Oct 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
47 53
14.46 266.53% 3 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Perform
n/a
n/a n/a 1 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
15 43
10.26 319.1% 4 Sep 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30 30
4.13 626.39% 2 Sep 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
12 12
1.8 566.67% 2 Sep 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
150 25
n/a n/a 9 Sep 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
31 28
13.57 106.34% 5 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
30 25
3.13 698.72% 3 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
74 73
29.76 145.3% 7 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 13
n/a n/a 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
14 20
1.79 1017.32% 5 Jul 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
29 29
24.52 18.27% 3 Jun 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
35
3.7 845.95% 2 Apr 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
10 10
0.65 1438.46% 1 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
23 20
1.58 1165.82% 3 Nov 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 7 Oct 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 13
1.53 749.67% 3 Apr 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
150 120
3.08 3796.1% 1 Mar 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 1 Oct 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 2 Aug 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
140
n/a n/a 1 Mar 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
36
n/a n/a 4 Dec 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
42
n/a n/a 1 Dec 9, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
12
n/a n/a 1 Sep 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
360000
n/a n/a 1 Jun 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Perform
n/a
n/a n/a 2 Mar 15, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Perform
n/a
n/a n/a 2 Nov 25, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
1.87 2573.8% 1 Oct 23, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
4620 1470
n/a n/a 2 Sep 25, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
225
n/a n/a 1 Aug 25, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
112 115
n/a n/a 2 May 12, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Perform
16 17
n/a n/a 2 May 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Perform
n/a
n/a n/a 4 Mar 31, 2020